Drug discovery

Data-driven federated learning in drug discovery with knowledge distillation

Vandenbruaene Nathalie — Tue, 18 Mar 2025 12:00:52 +0000

Data-driven federated learning in drug discovery with knowledge distillation

Yogesh Sabnis, Global CADD and Annie Delaunois, Non clinical Safety Evaluation

Vandenbruaene 鈥� Tue 18/03/2025 - 13:00

We鈥檙e proud to announce the publication of joint research on FLuID (Federated Learning Using Information Distillation) in Nature Machine Intelligence. This innovative approach has the potential to reshape how industries like pharmaceuticals collaborate while safeguarding sensitive data.

A key challenge for AI in scientific research is accessing high-quality data for impactful models. Valuable knowledge often remains locked in confidential corporate data silos, despite industries being more open to sharing non-competitive insights. Federated learning allows knowledge sharing while preserving data privacy but has limitations.

In the publication we introduce FLuID (federated learning using information distillation) tailored to drug discovery to maintain data privacy. Validated through public data and real-world collaboration among eight pharmaceutical companies, FLuID addresses domain shift challenges and enhances knowledge sharing. This leads to improved models for biological activity predictions, paving the way for a new generation of models with better performance and broader applicability.

Here鈥檚 how it works. Instead of sharing raw data, companies train private, local models and use them to annotate a shared public dataset. These annotations are then combined, creating a powerful blend of insights that organizations can leverage collaboratively. The process ensures complete privacy while producing models that outperform those built from individual datasets.

FLuID has already demonstrated its impact. By collaborating, multiple pharmaceutical companies have improved their ability to predict how chemical compounds interact with the human body, helping drive innovation and support drug safety predictions.

With its privacy-first design and scalable framework, we hope FLuID opens the door to ethical, large-scale collaboration across industries, paving the way for smarter, faster discoveries in fields where data security has traditionally been a barrier.

I invite you to explore this achievement and learn how FLuID is setting new standards for innovation in science and beyond by reading the full publication here.

innovation

61 Likes

Committed to drug discovery innovation

Vanco Vlastimil (金禾娱乐城 S.A.) — Tue, 19 Sep 2023 08:45:55 +0000

Committed to drug discovery innovation

Alexander Hillisch, Global Computer-aided drug design

Vanco Vlastimi鈥� Tue 19/09/2023 - 10:45

This week 金禾娱乐城 joined the OpenFold Artificial Intelligence (AI) Research Consortium. Joining this consortium reinforces our commitment to innovation in drug discovery and an aim to address the unmet medical needs of patients.

Participation in the consortium will help to enhance digital molecular design at 金禾娱乐城, using the power of deep learning, whilst contributing to the advancement of open-source research to the wider scientific community. Collaboration and partnerships are key to accelerate the impact of new technologies particularly in the rapidly evolving fields of artificial intelligence and computer-aided drug design (CADD).

The application of digital design at the molecular level has already enabled the discovery of some of our biologics-based treatments at 金禾娱乐城. Joining the OpenFold consortium will help 金禾娱乐城 to further contribute to the understanding of how and why molecules bind, in a collaborative, pre-competitive environment. The consortium will aid accurate state-of-the-art AI based structure prediction and assessment of interactions between protein:protein and protein:small molecules to deliver not only open science and innovation but also assist the design of novel treatments.

You can read the press release here.

innovation

Innovation OpenFold Artificial Intelligence Drug discovery CADD Computer-aided drug design

Comment:

Posted by hubertj0832737鈥�, 19 September 2023

Hi there to all, the contents existing at this website are in fact remarkable for people knowledge, well, keep up the good work fellows.

544 Likes

Closing the gap between the scientist and the patient

Vanco Vlastimil (金禾娱乐城 S.A.) — Wed, 26 Jul 2023 08:58:56 +0000

Closing the gap between the scientist and the patient

Jessica Williamson, US Protein Sciences

Vanco Vlastimi鈥� Wed 26/07/2023 - 10:58

In a world where scientific innovations are occurring at an unprecedented pace, it's more important than ever to bridge the gap between scientists and the patients they strive to help. At 金禾娱乐城 we believe a wave of innovation is helping reshape the healthcare landscape, with curiosity driving scientists and patients to come together to aid drug discovery and development so we can push the boundaries of what we can accomplish

Patient Involvement in Research

Partnering with patients enables us to delve deeper into our understanding of a disease and how it can profoundly affect individuals. Patients are experts in their own experiences, and their insights can provide valuable information to scientists. Furthermore, they can inform us on what aspects of a treatment or clinical trial participation they find most challenging, which we can work on overcoming.

Patient Involvement in Healthcare Innovation

Innovative digital technology is undoubtedly playing a crucial role in bridging the gap between the scientist and the patient. These technologies can enable individuals to actively participate in their healthcare by monitoring their daily health indicators, managing their medications, and tracking their physical activities. Additionally, by harnessing the power of artificial intelligence (AI) we have the potential to shift to a more precise approach to drug design and discovery which can also lead to more personalised medicines.

Driving Innovation Forward

As the driving force behind new discoveries in healthcare, scientists hold the key to unlocking innovations that have the potential to change lives. By fostering collaboration with patients, advocating for open access to knowledge, embracing digital health technologies, and learning more about the drivers of disease, we can close the gap between scientists and patients, creating a sustainable path to a healthier world for future generations.

Find out more about how innovation drives us forward here: Innovation is | 金禾娱乐城

innovation

Innovators Patient involvement Drug discovery Research and Development Innovation

439 Likes

Working collaboratively drives innovation and delivers value for patients

Vanco Vlastimil (金禾娱乐城 S.A.) — Mon, 13 Mar 2023 15:12:49 +0000

Working collaboratively drives innovation and delivers value for patients

Jiri Keirsse, Innovation Strategy & Transformation

Vanco Vlastimi鈥� Mon 13/03/2023 - 16:12

鈥業nnovation鈥� can mean many different things to many different people, but what unites each of these unique interpretations is an understanding that a key element is to challenge your thinking and the thinking of your colleagues. Challenging your own thinking and having others challenge it is integral to any culture which claims to have innovation at its heart.

At 金禾娱乐城 we recognize that the solitary exploration of ideas will never be as productive as when we work together. That鈥檚 why our culture not only fosters curiosity but also collaboration. Collaboration between groups some may perceive as separate; with patients, academia and industry partners, can lead to the whole becoming greater than the sum of its parts.

金禾娱乐城鈥檚 passion for challenge and collaboration, and our people鈥檚 intrinsic curiosity, create an environment in which innovation can thrive and where external connections are encouraged. Our strong network of collaborators helps challenge our thinking and exposes us to new ideas and ways of working.

This is particularly important in an era when technology is revolutionizing how pharmaceutical companies conduct research and develop medicines, as well as how patients experience healthcare and how healthcare professionals deliver it. We know that digital transformation has the potential to help us identify novel disease biology insights, and our digital partners can help us to realize this.

We鈥檝e been working closely with several high-profile collaborators in the digital space to combine their computational services, cloud, and artificial intelligence (AI) with our drug discovery and development capabilities. It is our hope and belief that digital platforms can support our scientists to discover and develop new differentiated medicines in a more efficient and innovative way.

The same pursuit of innovation and desire to challenge our status-quo, inspired and guided our journey into adeno-associated viral vector (AAV) gene therapy. We believe that this type of therapy will further enable our transition from symptomatic treatments to disease-modifying and potentially curative solutions. Initially we envision these solutions for well-defined monogenic patient populations, but with the ambition to address complex, multifactorial conditions in the future.

Patients remain at the center of everything we do here at 金禾娱乐城鈥� a philosophy that is demonstrated day in day out; apparent at every level, from corporate strategic decision-making to the hallway discussions with colleagues. We recognize that innovation and collaboration are key in our mission to serve patients and society. It鈥檚 a bold mission, but an incredibly exciting one, and we can鈥檛 wait to see where it takes us next.

If you enjoyed this article take a look at our dedicated 鈥榠nnovation is鈥� website here.

innovation

Innovators collaboration Patients Drug discovery Digital Transformation

487 Likes

We embrace collaboration

Vanco Vlastimil (金禾娱乐城 S.A.) — Fri, 14 Oct 2022 10:14:37 +0000

We embrace collaboration

Martin Citron, Neurology Early Solutions

Vanco Vlastimi鈥� Fri 14/10/2022 - 12:14

For over 30 years 金禾娱乐城 has worked in the field of epilepsy and our commitment has never been stronger. We are working towards a future where we can impact the underlying causes of certain epilepsies and change the course of disease. But such innovation isn鈥檛 easy, so we work hard at creating the right surroundings and culture that nurtures and fosters innovation. We will monitor for new disruptive technologies, expand our therapeutic modality platforms, and seek out partners that can help us pioneer new approaches to drug discovery.

So, we are pleased with the recent news that 金禾娱乐城 entered a drug discovery collaboration with GliaPharm. Co-founded by Prof. Pierre Magistretti, GliaPharm develops treatments for neurological and psychiatric disorders. Their therapeutic approach is to target glial cells, the 鈥渟upport cells鈥� of neurons, and to develop new drugs that target glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions. Under the collaboration, GliaPharm will use their proprietary GliaX technology platform to validate a series of therapeutic targets that we believe will enhance 金禾娱乐城's efforts in discovering drugs for epilepsy.

When you look at collaborations like this and the connectivity we have between our people, disciplines and technology, we think it鈥檚 a powerful R&D mix that we hope will enable us to develop solutions that move from symptomatic relief to those that could address the underlying causes of certain epilepsies.

So if you want to join a connected team who are in the pursuit of continuous innating then take a look at our R&D vacancies here.

innovation

R&D Drug discovery epilepsy GliaPharm collaboration

458 Likes

Partnering for Greater Impact with Microsoft in R&D

Vanco Vlastimil (金禾娱乐城 S.A.) — Wed, 23 Feb 2022 10:02:30 +0000

Partnering for Greater Impact with Microsoft in R&D

Wang Yuan, Data and Translational Sciences

Vanco Vlastimi鈥� Wed 23/02/2022 - 11:02

At 金禾娱乐城, our aim is to amplify the power of scientific innovation through digital transformation, ensuring we deliver the best individual experience so patients can live their best lives. As part of that effort, we are integrating artificial intelligence (AI) across the research and development organization to bring accelerated solutions to patients with unmet needs.

In drug discovery, specifically, we鈥檙e using AI methodologies to enhance 金禾娱乐城鈥檚 data science strategy. We want to increase the impact of a treatment through a deeper understanding of the biological causes of the disease and systematically provide better research data-driven insights to enable the faster discovery of therapeutic molecules.

To aid us in this research, we announced an expanded multi-year, strategic collaboration to combine Microsoft鈥檚 computational services, cloud, and AI with 金禾娱乐城鈥檚 drug discovery and development capabilities. As several drug discovery activities require the analysis of high-dimensional data sets or multi-modal unstructured information, Microsoft鈥檚 platform can support 金禾娱乐城鈥檚 scientists, including its data scientists, to discover new medicines in a more efficient and innovative way.

Our first use case is related to our Targeted Protein Degradation platform, where we are using AI-enabled workflows to better and more quickly collect information around disease-relevant biology and potential molecules of therapeutic value. Supported by Microsoft鈥檚 data science capabilities, our researchers aspire to ask questions on a whole new scale, and to review and compare millions of scientific literature in a more efficient manner.

By using advanced analytics, researchers can analyze and synthesize decades of scientific knowledge faster, with better interconnectivity to uncover underlying trends. Based on such extensive knowledge, scientists can make more informed data-driven decisions in the search of new medicines.

In addition to the scientific journey we have started here, this collaboration is also a cultural journey, exposing our industry to the novel solutions and enabling technologies provided by our partners in the technology sector, and inviting our partners to tackle more scientific challenges we face.

Watch the video now.

We are deepening our impact for people living with severe diseases by finding the right medicine for the right patient at the right time and working to further the good of society with a comprehensive collaboration strategy to support innovation. We are forging new relationships with leading researchers from academia and organizations, like Microsoft, to address some of today鈥檚 biggest healthcare challenges.

about ucb

Microsoft AI Artificial Intelligence Drug discovery R&D

970 Likes

Drug discovery

Data-driven federated learning in drug discovery with knowledge distillation

Leave a Comment

Committed to drug discovery innovation

Leave a Comment

Closing the gap between the scientist and the patient

Patient Involvement in Research

Patient Involvement in Healthcare Innovation

Driving Innovation Forward

Leave a Comment

Working collaboratively drives innovation and delivers value for patients

Leave a Comment

We embrace collaboration

Leave a Comment

Partnering for Greater Impact with Microsoft in R&D

Leave a Comment